Canaccord Genuity analyst Mark Massaro maintained a Sell rating on Meridian Bioscience Inc (VIVO) today and set a price target of $9. The company’s shares opened today at $13.67.
Massaro wrote:
“We reduce our FY’19 and FY’20 Adj. EPS, reiterate our SELL, and lower our PT to $9, which uses a 22x multiple on our F2021 Adj. EPS estimate of $0.41.”
According to TipRanks.com, Massaro is a 5-star analyst with an average return of 17.9% and a 60.2% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Quanterix Corporation, and Orasure Technologies.
Currently, the analyst consensus on Meridian Bioscience Inc is a Moderate Sell with an average price target of $12.67.
See today’s analyst top recommended stocks >>
The company has a one-year high of $19.84 and a one-year low of $11.23. Currently, Meridian Bioscience Inc has an average volume of 337.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Meridian Bioscience, Inc. engages in the development, manufacture, sale, and distribution of diagnostic test kits, antigens, reagents, and related products. It operates through the Diagnostics and Life Science segment.
